Cargando…
Optimizing treatment selection and sequencing decisions for first-line maintenance therapy of newly diagnosed advanced ovarian cancer
The incidence and mortality rates of ovarian cancer are increasing globally. Ovarian cancer is diagnosed at an advanced stage in 80% of women. After standard, platinum-based, front-line chemotherapy, poly (ADP-ribose) polymerase (PARP) inhibitors and antiangiogenic agents are successfully employed a...
Autores principales: | Goh, Jeffrey C.H., Gourley, Charlie, Tan, David S P, Nogueira-Rodrigues, Angélica, Elghazaly, Hesham, Edy Pierre, Marc, Giornelli, Gonzalo, Kim, Byoung-Gie, Morales–Vasquez, Flavia, Tyulyandina, Alexandra |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263863/ https://www.ncbi.nlm.nih.gov/pubmed/35813356 http://dx.doi.org/10.1016/j.gore.2022.101028 |
Ejemplares similares
-
Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial
por: DiSilvestro, Paul, et al.
Publicado: (2023) -
Management of relapsed ovarian cancer: a review
por: Giornelli, Gonzalo H.
Publicado: (2016) -
Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial
por: Colombo, Nicoletta, et al.
Publicado: (2021) -
Maintenance therapy for newly diagnosed epithelial ovarian cancer– a review
por: Nag, Shona, et al.
Publicado: (2022) -
Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma
por: Dimopoulos, Meletios A., et al.
Publicado: (2020)